<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931459</url>
  </required_header>
  <id_info>
    <org_study_id>ACU-001</org_study_id>
    <secondary_id>3U01AG053247</secondary_id>
    <nct_id>NCT04931459</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD</brief_title>
  <acronym>INTERCEPT-AD</acronym>
  <official_title>A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acumen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Acumen Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD),&#xD;
      placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and&#xD;
      pharmacodynamics (PD) of intravenous ACU193 when administered to participants diagnosed with&#xD;
      Mild Cognitive Impairment (MCI) or Mild Dementia due to Alzheimer's disease (AD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study ACU-001 is a placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple escalating doses of intravenous ACU193. A two-part single-ascending dose (SAD)/multiple-ascending dose (MAD) study design will be conducted in a population of individuals with early AD (MCI or mild dementia due to AD).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Nature of Treatment-Related Adverse Events (AE) or Serious Adverse Events (SAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>Baseline up to 20 weeks (SAD); 24 or 28 weeks (MAD)</time_frame>
    <description>Proportion of participants with AE, discontinuations due to AE or SAE, and withdrawals from the study due to AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Clinical Laboratory Tests</measure>
    <time_frame>Baseline up to 20 weeks (SAD); 24 or 28 weeks (MAD)</time_frame>
    <description>Incidence and clinically significant abnormal changes in clinical laboratory assessments (hematology, clinical chemistry, urinalysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in 12-Lead ECGs</measure>
    <time_frame>Baseline up to 20 weeks (SAD); 24 or 28 weeks (MAD)</time_frame>
    <description>Clinically significant abnormal changes in 12-Lead ECGs for PR, QRS, QT, QTcF, and QTcB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline up to 20 weeks (SAD); 24 or 28 weeks (MAD)</time_frame>
    <description>Presence of suicidal ideation as defined by a positive response to Question 5 on the C-SSRS suicide ideation section</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline (predose) up to 20 weeks (SAD); 24 or 28 weeks (MAD)</time_frame>
    <description>Brain magnetic resonance imaging (MRI) findings to assess amyloid-related imaging abnormalities (ARIA), including incidence of ARIA-E (edema) or ARIA-H (hemosiderosis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate Blood Levels of ACU193</measure>
    <time_frame>Up to 140 days post dose</time_frame>
    <description>Area under the concentration-time curve (AUC) from time zero to the time of last measurable concentration (AUCt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Maximum Blood Levels of ACU193</measure>
    <time_frame>Up to 140 days post dose.</time_frame>
    <description>Maximum observed blood concentration Cmax(obs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Time to Reach Maximum Blood Levels of ACU193</measure>
    <time_frame>Up to 140 days post dose.</time_frame>
    <description>Time to reach Tmax(obs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Blood Levels of ACU193</measure>
    <time_frame>Up to 140 days post dose.</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to infinity (AUC∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Clearance of ACU193</measure>
    <time_frame>Up to 140 days post dose</time_frame>
    <description>Clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Volume of Distribution of ACU193</measure>
    <time_frame>Up to 140 days post dose</time_frame>
    <description>Apparent volume of distribution at terminal phase (Vz)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>ACU193 Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 to 3 doses of ACU193 by intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Administration</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive 1 to 3 doses of matching ACU193 placebo by intravenous (IV) infusion.&#xD;
2 participants per cohort will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACU193</intervention_name>
    <description>Intravenous ACU193</description>
    <arm_group_label>ACU193 Administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous Placebo</description>
    <arm_group_label>Placebo Administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females ages 55 to 85 (inclusive).&#xD;
&#xD;
          2. Participant weighs at least 41 kg (90 lbs) and no more than 113 kg (250 lbs) before&#xD;
             study drug administration.&#xD;
&#xD;
          3. Female participants must be surgically sterile or be at least two years&#xD;
             post-menopausal or at least one year post-menopausal with an elevated follicle&#xD;
             stimulating hormone (FSH). Male participants with a female partner of child-bearing&#xD;
             potential must use adequate contraception.&#xD;
&#xD;
          4. Individual (or the participant's Legally Authorized Representative [LAR]) is able to&#xD;
             give informed consent.&#xD;
&#xD;
          5. Are willing and able to comply with scheduled visits, treatment plan, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
          6. Must meet all of the following clinical criteria for MCI due to AD or mild AD at&#xD;
             Screening:&#xD;
&#xD;
               1. Participant meets NIA-Alzheimer's Association (NIA-AA)criteria for MCI due to AD&#xD;
                  or probable AD.&#xD;
&#xD;
               2. A global Clinical Dementia Rating (CDR) of 0.5 or 1.0.&#xD;
&#xD;
               3. A Mini-Mental State Examination (MMSE) score between 20 and 30 (inclusive).&#xD;
&#xD;
               4. A positive amyloid positron emission tomography (PET) scan.&#xD;
&#xD;
          7. Must consent to apolipoprotein E (APOE) genotyping.&#xD;
&#xD;
          8. If using cholinesterase inhibitors or memantine to treat symptoms related to AD, doses&#xD;
             must be stable for at least four weeks prior to Baseline and willing to be stable&#xD;
             during the study.&#xD;
&#xD;
          9. Must have a reliable informant or caregiver who is willing and able to perform all&#xD;
             caregiver roles as specified in the caregiver Informed Consent Form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receipt of any investigational biological drug within less than one year of Baseline&#xD;
             or of any investigational small molecule drug within less than six months of Baseline.&#xD;
&#xD;
          2. Currently receiving or likely to require the following types of anticoagulants:&#xD;
             coumarins and indandiones, Factor Xa inhibitors, heparins, thrombin inhibitors.&#xD;
&#xD;
          3. Has known humanized monoclonal antibody allergy or hypersensitivity.&#xD;
&#xD;
          4. History of significant neurological disease, other than AD, that may affect cognition&#xD;
             or ability to complete the study, including but not limited to, other dementias,&#xD;
             serious infection of the brain, Parkinson´s disease, or adult epilepsy.&#xD;
&#xD;
          5. Has had magnetic resonance imaging (MRI) or computerized tomography (CT) of brain&#xD;
             within previous two years showing pathology that would be inconsistent with a&#xD;
             diagnosis of AD.&#xD;
&#xD;
          6. Has MRI with results showing greater than four amyloid-related imaging abnormalities&#xD;
             hemorrhage/hemosiderin deposition (ARIA-H), presence of any amyloid-related imaging&#xD;
             abnormalities edema/effusions (ARIA-E), or superficial siderosis.&#xD;
&#xD;
          7. Has any contraindications for MRI studies, including claustrophobia, the presence of&#xD;
             metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with&#xD;
             MRI.&#xD;
&#xD;
          8. Current serious or unstable clinically important illness that, in the judgment of the&#xD;
             Investigator, is likely to affect cognitive assessment including visual and hearing&#xD;
             impairment, deteriorate, or affect the participant's safety or ability to complete the&#xD;
             study, including psychiatric, hepatic, renal, gastroenterological, respiratory,&#xD;
             cardiovascular, endocrinological, immunologic, or hematologic disorders.&#xD;
&#xD;
          9. Has an ongoing or new clinically significant laboratory abnormality, as determined by&#xD;
             the Investigator.&#xD;
&#xD;
         10. Has a history or presence of clinically significant abnormal 12-lead electrocardiogram&#xD;
             (ECG) or an ECG with QT interval corrected using Fridericia's formula (QTcF) &gt;470 msec&#xD;
             for female participants or &gt;450 msec for male participants.&#xD;
&#xD;
         11. Within one year before Screening, any of the following: myocardial infarction;&#xD;
             moderate or severe congestive heart failure, New York Heart Association class III or&#xD;
             IV; hospitalization for, or symptom of, unstable angina; syncope due to orthostatic&#xD;
             hypotension or unexplained syncope; known significant structural heart disease (eg,&#xD;
             significant valvular disease, hypertrophic cardiomyopathy), or hospitalization for&#xD;
             arrhythmia.&#xD;
&#xD;
         12. History of seizure, transient ischemic attack (TIA), or stroke within the last 18&#xD;
             months.&#xD;
&#xD;
         13. History of clinically significant carotid or vertebrobasilar stenosis or plaque.&#xD;
&#xD;
         14. History of a malignant disease with the exception of resected cutaneous squamous cell&#xD;
             carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ&#xD;
             prostate cancer with a normal prostate-specific antigen posttreatment within the last&#xD;
             five years.&#xD;
&#xD;
         15. Current symptoms meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth&#xD;
             Edition, criteria for major depressive disorder or any current primary psychiatric&#xD;
             diagnosis other than AD if, in the judgment of the Investigator, the psychiatric&#xD;
             disorder or symptom is likely to confound interpretation of drug effect, affect&#xD;
             cognitive assessments, or affect the participant´s ability to complete the study.&#xD;
&#xD;
         16. Are a suicide risk, as determined by meeting any of the following criteria:&#xD;
&#xD;
               1. Suicide attempt within the six months prior to Baseline.&#xD;
&#xD;
               2. Suicidal ideation as defined by a positive response to Question 5 on the&#xD;
                  Columbia-Suicide Severity Rating Scale (C-SSRS) suicidal ideation section.&#xD;
&#xD;
               3. Significant risk of suicide, as judged by the site Investigator.&#xD;
&#xD;
         17. History of multiple concussions, significant head trauma, or objective change in&#xD;
             neuropsychological function within the last five years.&#xD;
&#xD;
         18. History of human immunodeficiency virus (HIV).&#xD;
&#xD;
         19. History of alcohol or drug abuse/dependence within the last five years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Siemers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Acumen Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Senetar, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Acumen Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russell Barton, MS</last_name>
    <role>Study Director</role>
    <affiliation>Acumen Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>463-235-7482</phone>
    <email>clinicaltrials@acumenpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Endpoints</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Martin</last_name>
      <phone>480-566-9090</phone>
      <email>bmartin@clinicalendpoints.com</email>
    </contact>
    <contact_backup>
      <last_name>Donnell Carmichael, Psy.D.</last_name>
      <phone>480-566-9090</phone>
      <email>dcarmichael@clinicalendpoints.com</email>
    </contact_backup>
    <investigator>
      <last_name>Allan Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn Quiles</last_name>
      <phone>954-455-5757</phone>
      <email>equiles@velocityclinical.com</email>
    </contact>
    <investigator>
      <last_name>Beth Safirstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charter Research</name>
      <address>
        <city>Lady Lake</city>
        <state>Florida</state>
        <zip>32159</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Blair</last_name>
      <phone>352-775-1000</phone>
      <email>Tina.Blair@CharterResearch.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Norton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Combined Research Orlando Phase I-IV</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yenilady Estevez</last_name>
      <phone>407-440-4493</phone>
      <email>Yenilady@clinicaltrialsorlando.com</email>
    </contact>
    <investigator>
      <last_name>Eric Carbonell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santos Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherley R. Valdez-Arroyo, MD</last_name>
      <phone>813-249-9100</phone>
      <email>sherleyresearchcenter@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sherley R Valdez-Arroyo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Nelson</last_name>
      <phone>404-537-1281</phone>
      <email>tamara.nelson@iresearchatlanta.com</email>
    </contact>
    <contact_backup>
      <last_name>Monica Mahathre</last_name>
      <phone>404-537-1281</phone>
      <email>monica.mahathre@iresearchatlanta.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kimball Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavioral Clinical Research, Inc.</name>
      <address>
        <city>North Canton</city>
        <state>Ohio</state>
        <zip>44720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Megan Smith, MA</last_name>
      <phone>330-493-1118</phone>
      <email>msmith@nb-cr.com</email>
    </contact>
    <contact_backup>
      <last_name>Shandell Mooney, RN</last_name>
      <phone>330-493-1118</phone>
      <email>smooney@nb-cr.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shishuka Malhotra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Diseases</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Mild dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

